Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, allopurinol/lesinurad (Duzallo®) cannot be endorsed for use within NHS Wales in adults for for the treatment of hyperuricaemia in gout patients who have not achieved target serum uric acid levels with an adequate dose of allopurinol alone. |
||
|
||
Medicine details |
||
| Medicine name | allopurinol/lesinurad (Duzallo®) | |
| Formulation | 200 mg/200 mg and 300 mg/200 mg film-coated tablet | |
| Reference number | 3588 | |
| Indication | In adults for for the treatment of hyperuricaemia in gout patients who have not achieved target serum uric acid levels with an adequate dose of allopurinol alone. |
|
| Company | Grunenthal Ltd | |
| BNF chapter | Musculoskeletal & joint diseases | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 19/12/2018 | |